Results 271 to 280 of about 119,295 (311)
Some of the next articles are maybe not open access.
Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases
Melanoma Research, 2015The impact of BRAF mutations in metastatic melanoma on the incidence of brain metastases and melanoma prognosis and the effect of BRAF inhibitors on the incidence of brain metastases has not been defined. Therefore, a retrospective analysis of patients with metastatic melanoma treated at three institutions was carried out to examine the impact of BRAF ...
Gummadi T +9 more
openaire +3 more sources
BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
Expert Opinion on Pharmacotherapy, 2015BRAF inhibition alone has achieved unprecedented efficacy results in patients affected by BRAF-mutated advanced melanoma. Since these findings, it was postulated that dual inhibition of BRAF and other components of the RAS/RAF/MEK/ERK MAPK pathway (such as MEK) would be superior to BRAF inhibition as monotherapy. A series of recent clinical trials have
Juliet, Richman +3 more
openaire +2 more sources
The Cancer Journal, 2011
Selective BRAF inhibitors have recently emerged as a new standard treatment for patients with metastatic melanoma harboring activating BRAF mutations. Inhibition of the MAP kinase pathway and initial evidence of antitumor effects are very reliably observed. However, many patients experience short-lived responses, whereas others are durable.
openaire +2 more sources
Selective BRAF inhibitors have recently emerged as a new standard treatment for patients with metastatic melanoma harboring activating BRAF mutations. Inhibition of the MAP kinase pathway and initial evidence of antitumor effects are very reliably observed. However, many patients experience short-lived responses, whereas others are durable.
openaire +2 more sources
BRAF and MEK inhibitors in BRAF-mutant melanoma
The Lancet Oncology, 2012Patients with melanoma and the Val600 BRAF mutation benefi t from combined inhibition of BRAF and MEK, according to a new study. Selective BRAF inhibitors such as dabrafenib and MEK inhibitors such as trametinib have individually been shown to increase progressionfree survival (PFS) and overall survival in Val600 BRAF-mutant melanoma.
openaire +1 more source
Inhibition of BRAF and MEK in BRAF-mutant melanoma
The Lancet, 2015Keiran S M, Smalley, Vernon K, Sondak
openaire +2 more sources
Response to BRAF and MEK Inhibitors in BRAF Thr599dup–Mutated Melanoma
JCO Precision Oncology, 2022Marion Oberlé +11 more
openaire +2 more sources
2018
?? 40???60% ?????????????? ???????????????? ???????? ???????????????? ?????????????? ???????????????? BRAF, ???????????????????? ?????????????? ???????????????? ???????????????????????????? ?????????????????? ???????????????????????????????? ???????????? BRAF ??, ????????????????????????????, ?????????????????????? ?????????????? ???? ???????? MAPK/ERK.
Chapman, P.B., Hauschild, A., Robert, C.
openaire +1 more source
?? 40???60% ?????????????? ???????????????? ???????? ???????????????? ?????????????? ???????????????? BRAF, ???????????????????? ?????????????? ???????????????? ???????????????????????????? ?????????????????? ???????????????????????????????? ???????????? BRAF ??, ????????????????????????????, ?????????????????????? ?????????????? ???? ???????? MAPK/ERK.
Chapman, P.B., Hauschild, A., Robert, C.
openaire +1 more source
In vitro characterization of BRAF(V600E) splicing variants: BRAF-220 and BRAF-204
BRAF is a kinase that can be found mutated (V600E) in several cancer types, such as melanoma, and, because of its cancer driver effect, it has been studied as therapeutic target. Irrespective of its mutational status, BRAF(V600E) is always expressed as a pool of at least two transcripts: the canonical one, called BRAF-ref (“reference”, ENST00000646891 ...openaire +1 more source